Nutrition and Pharmacological Algorithm for Oncology Patients Study
Loss of appetite is a common symptom of patients with cancer and can cause distress which impacts patients and caregivers. Patients diagnosed with head/neck, lung or pancreatic cancer will be recruited for this study to decrease the suffering and distress associated with eating during cancer treatment and improve the quality of life of patients by implementing an algorithm utilizing nutrition intervention and appetite stimulants.
Checked against the public recordLast updated Nov 16, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Phase 4
- Sponsor
- Montefiore Medical Center
- Interventions being studied
- Drug: Dexamethasone; Drug: Dronabinol; Drug: Mirtazapine; Behavioral: Nutrition Intervention
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Patients with a diagnosis of head/neck, lung, pancreatic cancer, or metastatic cancer from any solid tumor 2. Planned, ongoing, or recently treated patient (within the past 30 days) with chemotherapy, immunotherapy, and/or intravenous targeted biologic therapy 3. No previous use of appetite stimulants 4. All patients must sign study specific informed consent prior to being included in the study 5. No contraindication to appetite stimulants Exclusion Criteria: 1. Patient \<18 years old 2. Contraindication to appetite stimulants
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Montefiore HospitalThe Bronx, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 16, 2022. Always confirm current availability with the study team.